Status:
COMPLETED
Genetic Analysis of Familial Melanoma
Lead Sponsor:
National Human Genome Research Institute (NHGRI)
Conditions:
Melanoma
Eligibility:
All Genders
Brief Summary
In collaboration with members of The International Melanoma Consortium, we propose to study melanoma in families lacking mutations in the cyclin-dependent kinase inhibitor 2 (CDKN2 or p16) gene, or th...
Detailed Description
In collaboration with members of The International Melanoma Genetics Consortium, we propose to study melanoma in families lacking mutations in the cyclin-dependent kinase inhibitor 2 (CDKN2A), or the ...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Inclusion into this study was restricted to families containing at least three CMM cases with DNA available for genotyping, and CDKN2A and CDK4 involvement and had been excluded.
- All families must be mutation negative for both CDKN2A and CDK4.
- This study will also include families with at least one case of ocular and two cases of other cutaneous melanomas, or at least 2 ocular melanomas (except where they occur in parent and child).
- EXCLUSION CRITERIA:
- Any family showing evidence of haplotype sharing in the 9p21-p22 region, where CDKN2A is located, was also excluded.
Exclusion
Key Trial Info
Start Date :
March 4 1999
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 7 2011
Estimated Enrollment :
3000 Patients enrolled
Trial Details
Trial ID
NCT00339404
Start Date
March 4 1999
End Date
March 7 2011
Last Update
July 2 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Human Genome Research Institute (NHGRI), 9000 Rockville Pike
Bethesda, Maryland, United States, 20892